Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPRESS: PCSK9i in ACS
NCT06791031Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
01
Overview
Randomised, open-label trial of evolocumab, alirocumab and inclisiran in acute coronary syndrome (ACS) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Absolute change in the minimum fibrous cap thickness of target lesions at 6 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
evolocumabalirocumabinclisiran
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06791031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791031.